Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
25
6
6
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
8.0%
2 terminated/withdrawn out of 25 trials
0.0%
-86.5% vs industry average
4%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Role: lead
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Role: lead
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Role: lead
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Role: collaborator
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
Role: lead
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Role: lead
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Role: lead
U87 CART in Treatment of Advanced Solid Tumor
Role: lead
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Role: collaborator
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Role: lead
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Role: lead
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Role: lead
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Role: lead
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Role: lead
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Role: lead
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Role: lead
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment
Role: lead
Anti-BCMA CAR T-Cell Therapy for R/R ITP
Role: collaborator
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL
Role: collaborator
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
Role: collaborator